Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. We can tell because the short person is up early and a parade of cars has floated by the Pharmalot campus. As for us, we are rummaging through emails and trying to decide what to do next. There is no shortage of options, though. To help us, we are brewing a cup of stimulation. Please feel free to join us. As always, here are some items of interest to help you on your own journey, such as it is. Hope all goes well and keep in touch. …

Marc Short, chief of staff to Vice President Mike Pence, owns between $506,043 and $1.64 million worth of individual stocks in companies doing work related to the pandemic response — holdings that could run afoul of conflict-of-interest laws, NPR reports. Many of the companies in which Short and his wife hold stock — including Abbott Labs (ABT), Gilead Sciences (GILD), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) — have been directly affected by or involved in the work of the Coronavirus Task Force, chaired by Pence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy